Aquestive Therapeutics, Inc.
AQST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $328,771 | $276,941 | $324,670 |
| - Cash | $129,063 | $60,536 | $68,657 | $71,546 |
| + Debt | $120,373 | $126,257 | $39,135 | $38,004 |
| Enterprise Value | – | $394,492 | $247,419 | $291,128 |
| Revenue | $12,807 | $10,003 | $8,720 | $11,867 |
| % Growth | 28% | 14.7% | -26.5% | – |
| Gross Profit | $8,301 | $5,442 | $5,068 | $7,347 |
| % Margin | 64.8% | 54.4% | 58.1% | 61.9% |
| EBITDA | -$11,034 | -$9,132 | -$15,763 | -$12,698 |
| % Margin | -86.2% | -91.3% | -180.8% | -107% |
| Net Income | -$15,446 | -$13,548 | -$22,930 | -$17,055 |
| % Margin | -120.6% | -135.4% | -263% | -143.7% |
| EPS Diluted | -0.14 | -0.14 | -0.24 | -0.19 |
| % Growth | 0% | 41.7% | -26.3% | – |
| Operating Cash Flow | -$12,649 | -$7,914 | -$23,400 | -$6,489 |
| Capital Expenditures | -$235 | -$107 | -$135 | -$15 |
| Free Cash Flow | -$12,884 | -$8,021 | -$23,535 | -$6,504 |